Turn Therapeutics (TTRX)
Develops GX-03 for skin disease while licensing medical-device products.
Something off on this page? Send us feedback.
Develops the topical GX-03 candidate for atopic dermatitis and a subsequent onychomycosis program, supported by the PermaFusion drug-performance platform. The business combines internal drug development with third-party licensing or sales of a legacy FDA-cleared device portfolio.
GX-03 is the central program in a dermatology-focused clinical-development portfolio. The topical candidate is in an adaptive Phase 2 study for atopic dermatitis, while the company describes onychomycosis as a subsequent drug-development program. PermaFusion, a platform intended to enhance drug performance, underpins this work. Earlier GX-03 wound-care applications and other FDA-cleared devices form a separate device legacy.
Operations pair third-party licensing or sale of medical-device products with internal drug development. Manufacturing, packaging, and sterilization are performed in the United States. Progress depends on clinical-trial results, regulatory clearances or approvals, commercial partners, manufacturing, intellectual-property protection, and access to capital.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.3M · Total debt $6.1M · Total assets $17.0M · Shareholders' equity $686.9K
- Revenue
- $0
- Operating income
- −$1.6M
- Net income
- −$5.8M
No dividends on record.
| Institutions | 3.88% | 1.16M shares | |
|---|---|---|---|
| 29 holders · as of Jun 30, 2026 | |||
| Other | 96.12% | 28.63M shares | |
| remainder | |||
29.79M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Steel Peak Wealth Management LLCInstitution | 0.84% | 249,456 | as of Jun 30, 2026 |
Ieq Capital, LLCInstitution | 0.76% | 227,396 | as of Jun 30, 2026 |
DDFG, IncInstitution | 0.36% | 107,829 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.25% | 74,301 | as of Jun 30, 2026 |
Wellington Shields & Co., LLCInstitution | 0.22% | 65,732 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Incyte
Topical JAK option for mild-to-moderate atopic dermatitis
- Arcutis Biotherapeutics
Topical PDE4 option for mild-to-moderate atopic dermatitis
- Organon
Once-daily steroid-free topical for atopic dermatitis
- Sanofi (ADR)
IL-4/IL-13 biologic franchise for moderate-to-severe atopic dermatitis
- Pfizer
Topical PDE4 therapy for mild-to-moderate atopic dermatitis
- Eli Lilly
IL-13 biologic for moderate-to-severe atopic dermatitis
- Bausch Health
Topical antifungal for toenail onychomycosis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Turn Therapeutics | $14.25 | −6.81% | $455.5M | — | — | — | — |
| Incyte | $124.41 | −1.99% | $25.73B | 16.2 | 51.5 | 4.4 | +37.7% |
| Arcutis Biotherapeutics | $26.38 | −5.04% | $3.47B | 133.2 | 33.4 | 7.5 | +59.3% |
| Organon | $13.74 | +0.26% | $3.60B | 17.8 | 3.9 | 0.6 | +0.5% |
| Sanofi (ADR) | $41.49 | −2.40% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Pfizer | $28.18 | +0.88% | $159.19B | 36.9 | 10.1 | 2.5 | +2.6% |
| Eli Lilly | $1,147.64 | −1.92% | $1.10T | 39.3 | 28.1 | 13.8 | +47.7% |
| Bausch Health | $5.74 | −1.29% | $2.17B | — | 1.3 | 0.2 | +11.2% |
| Median | 38.1 | 19.1 | 2.5 | +11.2% |